New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareFollistatin vs Follistatin 344

Follistatin vs Follistatin 344

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
Follistatin
Anabolic & IGF
Follistatin 344
Summary
Follistatin is an endogenous glycoprotein that acts as a potent inhibitor of myostatin and activin, two proteins that limit muscle growth. By binding and neutralizing myostatin, follistatin removes the primary brake on skeletal muscle hypertrophy, enabling significant muscle growth beyond normal physiological limits. It is distinct from its isoforms Follistatin 315 and Follistatin 344 in tissue distribution and binding affinity.
Follistatin 344 is a recombinant form of the endogenous follistatin protein. It inhibits myostatin and activin — the primary negative regulators of muscle growth — potentially removing the genetic ceiling on muscle development. It is one of the most theoretically powerful anabolic compounds but is experimental with limited human data.
Half-Life
~3–5 hours (endogenous form)
~24–36 hours
Admin Route
IM, SubQ
SubQ, IM
Research
Typical Dose
50–100 mcg per injection site
100 mcg
Frequency
Every other day or 2–3x per week
Once daily
Key Benefits
  • Potent myostatin inhibition enabling supraphysiological muscle growth
  • Increases skeletal muscle mass and fiber size
  • May accelerate recovery from muscle injury
  • Potential benefits in muscular dystrophy and sarcopenia
  • Synergistic with IGF-1 and growth hormone in anabolic protocols
  • Animal studies show dramatic increases in muscle mass
  • Reduces muscle fibrosis in dystrophic models
  • Inhibits myostatin — removes muscle growth ceiling
  • Significant increases in muscle mass and strength
  • Reduces fat mass
  • Promotes bone density
  • May stimulate hair follicle cycling
  • Anti-fibrotic effects in muscle tissue
  • Synergistic with IGF-1 and other anabolic peptides
Side Effects
  • Potential for excessive muscle growth if doses are not controlled
  • FSH suppression with implications for fertility in women
  • Theoretical risk of cardiac hypertrophy with prolonged high-dose use
  • Limited human safety data available
  • +1 more
  • Muscle soreness (from rapid hypertrophy)
  • Potential reproductive effects (activin inhibition)
  • Unknown long-term safety profile
  • Possible esophageal effects at high doses (animal data)
Stacks With